Core Viewpoint - The article highlights the increasing trend of interim dividend announcements among A-share listed companies, with a total proposed payout of 829.02 billion yuan as of August 13, 2025, reflecting a strong commitment to shareholder returns and stable financial management [1] Group 1: Interim Dividend Trends - As of August 13, 2025, 65 A-share listed companies have disclosed their interim dividend plans, with a total proposed payout of 829.02 billion yuan [1] - Several companies are initiating interim dividends for the first time, with industry leaders leading the way in distributing substantial dividends [1][2] - The trend of increasing cash dividends aligns with regulatory encouragement and investor expectations, indicating a positive market reception [1] Group 2: Company-Specific Dividend Plans - Hikvision plans to distribute a cash dividend of 4 yuan per 10 shares, totaling approximately 3.6 billion yuan, supported by a revenue of 418.18 billion yuan and a net profit of 56.57 billion yuan for the first half of the year [2] - Changshu Bank has achieved double-digit growth in revenue and net profit for 16 consecutive quarters, proposing a cash dividend of 0.15 yuan per share, totaling 4.97 billion yuan, which is 25.27% of its net profit [3] - Weisheng Information plans to distribute a cash dividend of 2.5 yuan per 10 shares, totaling 1.22 billion yuan, with a net profit of 3.05 billion yuan, reflecting a 40% payout ratio [3] Group 3: Industry Leaders and Their Performance - China Mobile reported a revenue of 543.8 billion yuan and a net profit of 84.2 billion yuan, proposing an interim dividend of 2.75 HKD per share, totaling approximately 54.2 billion yuan [4] - China Unicom achieved a revenue exceeding 200 billion yuan and a profit of 17.7 billion yuan, proposing a dividend of 0.1112 yuan per share, totaling around 3.48 billion yuan [5] - CATL, benefiting from dual business segments, reported a revenue of 178.9 billion yuan and a net profit of 30.5 billion yuan, proposing a cash dividend of 10.07 yuan per 10 shares, totaling 4.57 billion yuan [5] - WuXi AppTec achieved a revenue of 207.99 billion yuan and a net profit of 85.61 billion yuan, proposing a cash dividend of 3.5 yuan per 10 shares, totaling 1.003 billion yuan [5]

香港股市创下自五月初以来的最佳单日表现。 主要推动因素包括：1. 延续昨日的利息补贴政策利好；2. 地缘政治局势逐步改善（关税休战虽已提前敲 定但基本符合预期）；3. 科技巨头财报季前的风险偏好升温。 南下资金净卖出 10 亿美元，而恒生指数大幅上涨，印证了本地市场风险情绪正在积聚动能。 港股成交额环比暴增 32%，南下交易占比从本周稍早的 30% 回落至 27%，再次表明外资买入是主要推 手。做空比例最高的股票仅上涨 2.7%，未呈现显著超额收益，说明即便存在轧空规模有限。 资金流向上 —— 高盛的交易平台买入呈现 1.2 倍净卖出状态。消费和科技板块是平台最活跃的主题 （双向交易并存，但消费股更适合卖出而科技股更宜买入）。消费板块呈现双向流动，餐饮类股遭遇部 分抛售，而普拉达等零售股则买卖交投活跃。科技板块中，持续在硬科技领域获得买单，但对腾讯音乐 等冲高个股转为卖出。网易也获得较大力度买入。医疗保健 / 制药板块更受青睐 —— 翰森制药虽呈双 向交易但买方更占优势。 从行业板块来看，医疗保健、科技和消费板块领涨 —— 在中国政府宣布对符合条件的个人消费贷款实 施贴息计划后，国内零售商与消费医疗企业的股价 ...

一、沪深股通前十大成交 今日沪股通总成交金额为1378.54亿，深股通总成交金额为1393.38亿。 | | | | D 沪股通( 8月13日 | | | | --- | --- | --- | --- | --- | --- | | 排名 | 股票代码 | 股票名称 | 成父金額 | 前一交易日净买入额 | 法幅(%) | | | | | (亿元) | (亿元) | | | 1 | 600519 | 贵州茅台 | 31.54 | | | | 2 | 603259 | 药明康德 | 23.94 | | | | 3 | 688256 | 寒武纪 | 22.19 | | | | 4 | 601138 | 工业富联 | 19.05 | | | | 5 | 600276 | 恒瑞医药 | 16.49 | | | | 6 | 600036 | 沼商银行 | 16.06 | | | | 7 | 688041 | 海光信息 | 15.00 | | | | 8 | 601318 | 中国平安 | 14.75 | | | | 9 | 600183 | 生益科技 | 13.33 | | | | 10 | 600030 | 中信证 ...

文/新苏商记者张静文 具体来看，连云港恒瑞医药以4156亿元的总市值排在江苏A股上市公司市值第一位。今年以来，恒瑞医 药发展稳健，7月底，公司与英国制药巨头GSK达成约120亿美元合作协议，首付款5亿美元，刷新中国 药出海纪录。 前不久，美国《制药经理人》杂志发布了2025年全球制药企业50强榜单，恒瑞医药位列第46名，排名上 升2位。 同属医药生物行业的无锡药明康德以2894亿元的总市值紧随其后。2025上半年财报显示，上半年药明康 德实现营收207.99亿元，同比增长20.64%，实现归母净利润85.61亿元，同比增长101.92%。财报公布次 日，药明康德股价大涨7.72%。 东山精密在7月17日市值首次突破千亿大关，当天股票涨停。截至今日收盘，公司最新市值约为1090亿 元。从2024年年初至今，东山精密股价从17.71元/股涨至59.5元/股，涨幅高达236%。 8月13日，市场全天震荡走高，沪指突破去年10月8日高点，创近4年新高。沪深两市全天成交额2.15万 亿元，较上个交易日放量2694亿元，时隔114个交易日重回2万亿元上方，全市场超2700只个股上涨。 得益于行业好转和出海业务增长迅猛，徐 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) ...

证券之星消息，8月13日医疗服务板块较上一交易日上涨4.02%，创新医疗领涨。当日上证指数报收于 3683.46，上涨0.48%。深证成指报收于11551.36，上涨1.76%。医疗服务板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗服务板块主力资金净流入19.62亿元，游资资金净流出7449.63万元，散户资 金净流出18.88亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603259 | 药明康德 | = 11.30 乙 | 11.46% | -1.00 Z | -1.02% | -10.30 Z | -10.45% | | 300759 康龙化成 | | 2.48亿 | 9.09% | 4825.42万 | 1.77% | -2.96 Z | - ...

智通财经APP讯，药明康德(02359)发布公告，该公司于2025年8月13日斥资2799.04万元人民币回购29.2 万股A股，每股回购价格为91.91-98.83元人民币。 ...

Market Overview - A-shares experienced a significant rally, with the Shanghai Composite Index achieving an 8-day winning streak and reaching a new high since December 2021, closing at 3683.46 points, up 0.48% [1] - The total trading volume in the A-share market exceeded 2 trillion yuan for the first time since February 27, with a total of 21,756 billion yuan traded [1] - The Hong Kong stock market also saw substantial gains, with the Hang Seng Index rising over 2% and the Hang Seng Tech Index increasing over 3% [1] AI Industry - AI-related stocks surged, with notable gains including Guangku Technology and Robotech both hitting the 20% limit up, and Industrial Fulian also reaching the limit up [2][4] - Industrial Fulian reported a revenue of 360.76 billion yuan for the first half of 2025, a year-on-year increase of 35.58%, and a net profit of 12.11 billion yuan, up 38.61% [4][5] - The demand for AI servers is expected to grow significantly, driven by increased capital expenditures from major North American cloud service providers [4][5] Innovative Pharmaceuticals - The innovative drug sector saw strong performance, with Shouyao Holdings hitting the 20% limit up, and other companies like Microchip Biotech and WuXi AppTec also posting significant gains [6][8] - The National Medical Insurance Administration has established a "new drug pricing mechanism," which is expected to provide innovative drug manufacturers with greater pricing flexibility and efficiency [8] Humanoid Robotics - The humanoid robotics sector showed renewed activity, with companies like Shenglan Co. and Jieke Co. seeing substantial increases in stock prices [9][11] - The World Robot Conference held in Beijing highlighted advancements in embodied intelligent robots, with local governments offering subsidies for robot purchases [9][11] - The industry is expected to benefit from various supportive policies and events, including the upcoming World Humanoid Robot Games and other robotics-related conferences [11]

Market Overview - A-shares experienced a significant rally, with the Shanghai Composite Index achieving an 8-day winning streak and reaching a new high since December 2021, closing at 3683.46 points, up 0.48% [1] - The total trading volume in the A-share market exceeded 2 trillion yuan for the first time since February 27, indicating increased market activity [1] - The Hong Kong stock market also saw substantial gains, with the Hang Seng Index rising over 2% and the Hang Seng Tech Index increasing by more than 3% [1] AI Industry - Stocks in the AI industry chain surged, with notable gains including Guangku Technology and Robotech both hitting the 20% limit up, and Industrial Fulian also reaching the limit up [3][4] - Industrial Fulian reported a revenue of 360.76 billion yuan for the first half of 2025, a year-on-year increase of 35.58%, and a net profit of 12.113 billion yuan, up 38.61% [5] - The company attributed its growth to breakthroughs in AI technology and an expected increase in capital expenditure from major North American cloud service providers, which will drive demand for high-end AI servers [5][6] Innovative Drug Sector - The innovative drug sector saw strong performance, with Shouyao Holdings hitting the 20% limit up and other companies like Microchip Biotech and WuXi AppTec also experiencing significant gains [8][9] - The National Medical Insurance Administration has established a "new drug pricing mechanism," which is expected to provide innovative drug manufacturers with greater pricing flexibility and efficiency [10][11] Humanoid Robot Sector - The humanoid robot sector showed renewed activity, with companies like Shenglan Co. and Jieke Co. seeing substantial increases in stock prices, with several stocks hitting the limit up [13][14] - The World Robot Conference held in Beijing highlighted advancements in embodied intelligent robots, with local governments offering subsidies for robot purchases to stimulate the market [15]

创新药概念股，再度异动！ 在高位盘整多日之后，创新药概念股今日再度走强。临近午盘时分，首药控股直线拉升至20cm涨停，海思科盘中也触及涨停，药明康德、美迪西、常山 药业、凯莱英等纷纷走强。 从消息面来看，国家医保局12日对2025年国家医保药品目录初步形式审查结果进行公示，534个药品通过形式审查，较2024年明显增加。首次设立的商保 创新药目录共121个药品通过审查。有券商指出，在医保基础上补充发展商保，有利于具有创新性和临床价值的高价创新药落地。 创新药概念股拉升 8月13日，A股三大指数震荡攀升，创业板指大涨近3%。液冷服务器、CPO、PEEK材料、券商等板块纷纷走强。临近午盘时，创新药概念股也集体发力， 首药控股率先20cm涨停。紧随其后，海思科也被资金拉升至涨停板，股价创出历史新高。美迪西、上海谊众、仙琚制药、昭衍新药、常山药业、凯莱英 等纷纷跟涨。午后，行业巨头药明康德的股价涨幅一度超过8%，市值逼近2900亿元。 从消息面来看，创新药板块近期的利好消息相当密集。8月12日，国家医保局对2025年国家医保药品目录初步形式审查结果进行公示，534个药品通过形式 审查。 值得关注的是，2025年目录调 ...